Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schoffski, P; Wozniak, A; Kasper, B; Aamdal, S; Leahy, M G; Rutkowski, P; Bauer, S; Gelderblom, H; Italiano, A; Lindner, L H; Hennig, I; Strauss, S; Zakotnik, B; Anthoney, A; Albiges, L; Blay, J -Y; Reichardt, P; Sufliarsky, J; van der Graaf, W T A; Debiec-Rychter, M; Sciot, R; Van Cann, T; Marreaud, S; Raveloarivahy, T; Collette, S; Stacchiotti, S
[Article]
Annals of Oncology.
29(3):758-765, March 2018.
(Format: HTML)